Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988401 · ClinicalTrials.gov registry record · Phase 1
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
A Phase 1 study of Multiple Sclerosis (Relapsing Remitting) and Multiple Sclerosis, Secondary Progressive, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT02988401: Completed Phase 1 study of Multiple Sclerosis (Relapsing Remitting) and Multiple Sclerosis, Secondary Progressive, sponsored by Johns Hopkins University.
NCT02988401 is a Phase 1 study of Multiple Sclerosis (Relapsing Remitting) and Multiple Sclerosis, Secondary Progressive that has completed, run by Johns Hopkins University. The registered enrollment target is 105 participants, below the 559-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02988401, a Phase 1 study of Multiple Sclerosis (Relapsing Remitting) and Multiple Sclerosis, Secondary Progressive, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS). It is also being done to evaluate if intranasal insulin improves cognitive function in people with MS and to evaluate how it might be working.
Primary Outcome
This task will be performed at five study visits. The SDMT is one of the most commonly used tests to assess processing speed in the MS population and is included in the Minimal Assessment of Cognitive Function in MS (MACFIMS). Higher scores reflect a better outcome (range 0 to 110). In order to account for all contributed data (even for those who did not complete the study but contributed some post-randomization data in the active study phase), the primary analyses include the SDMTs acquired wit
Conditions Studied
Interventions
- DRUG Insulin
- DRUG Placebo (Sterile diluent)
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2021-12-17 |
| Phase | Phase 1 |
What the finished NCT02988401 record still lists
NCT02988401 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 559-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 2 interventions - of which Insulin is the first listed.
NCT02988401 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02988401 about?
NCT02988401 is a clinical study titled "Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis". This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS). It is also being done to evaluate if intranasal insulin improves cognitive function in people with MS and to evaluate how it might be working.
What is the current status of trial NCT02988401?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2017-12-01. Estimated completion is 2021-12-17.
What conditions does trial NCT02988401 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive.
What interventions are being tested in trial NCT02988401?
The interventions under investigation include: Insulin (DRUG), Placebo (Sterile diluent) (DRUG).
Who is sponsoring clinical trial NCT02988401?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02988401 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02988401's enrollment target sits among peer trials
105 14th of 29 higher than 16 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
RECRUITING · Phase 1
-
Safety of RG2077 in Patients With Multiple Sclerosis
COMPLETED · Phase 1
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI